Publications
See a complete PubMed list of publications by Ekihiro Seki, MD, PhD.
Selected Key Publications
- Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22. Wang Q, Kim SY, Matsushita H, Wang Z, Pandyarajan V, Matsuda M, Ohashi K, Tsuchiya T, Roh YS, Kiani C, Zhao Y, Chan M, Devkota S, Lu SC, Hayashi T, Carson DA, Seki E., Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2020868118. PMID:33443222
- Hyaluronan synthase 2-mediated hyaluronan production mediates Notch1 activation and liver fibrosis. Yang YM, Noureddin M, Liu C, Ohashi K, Kim SY, Ramnath D, Powell EE, Sweet MJ, Roh YS, Hsin IF, Deng N, Liu Z, Liang J, Mena E, Shouhed D, Schwabe RF, Jiang D, Lu SC, Noble PW, Seki E. Sci Transl Med. 2019 Jun 12;11(496). pii: eaat9284. doi: 10.1126/scitranslmed.aat9284. PMID: 31189722
- NOD-like receptor C4 Inflammasome Regulates the Growth of Colon Cancer Liver Metastasis in NAFLD. Ohashi K, Wang Z, Yang YM, Billet S, Tu W, Pimienta M, Cassel SL, Pandol SJ, Lu SC, Sutterwala FS, Bhowmick N, Seki E. Hepatology. 2019 Nov;70(5):1582-1599. doi: 10.1002/hep.30693. Epub 2019 May 23. PMID: 31044438
- Murine macrophage autophagy protects against alcohol-induced liver injury by degrading interferon regulatory factor 1 (IRF1) and removing damaged mitochondria. Liang S, Zhong Z, Kim SY, Uchiyama R, Roh YS, Matsushita H, Gottlieb RA, Seki E. J Biol Chem. 2019 Aug 16;294(33):12359-12369. doi: 10.1074/jbc.RA119.007409. Epub 2019 Jun 24. PMID: 31235522
- Neurotropin Inhibits Lipid Accumulation by Maintaining Mitochondrial Function in Hepatocytes via AMPK Activation. Wang Q, Wang Z, Xu M, Tu W, Hsin IF, Stotland A, Kim JH, Liu P, Naiki M, Gottlieb RA, Seki E. Front Physiol. 2020 Aug 6;11:950. doi: 10.3389/fphys.2020.00950. PMID: 32848877
- TAK1-mediated autophagy and fatty acid oxidation prevent hepatosteatosis and tumorigenesis. Inokuchi-Shimizu S, Park EJ, Roh YS, Yang L, Zhang B, Song J, Liang S, Pimienta M, Taniguchi K, Wu X, Asahina K, Lagakos W, Mackey MR, Akira S, Ellisman MH, Sears DD, Olefsky JM, Karin M, Brenner DA, Seki E. J Clin Invest. 2014 Aug;124(8):3566-78. doi: 10.1172/JCI74068. Epub 2014 Jul 1. PMID: 24983318
- Transforming growth factor-β signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Gastroenterology. 2013 May;144(5):1042-1054.e4. doi: 10.1053/j.gastro.2013.01.056. Epub 2013 Feb 4. PMID: 23391818
- Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Proc Natl Acad Sci U S A. 2010 Jan 12;107(2):844-9.doi: 10.1073/pnas.0909781107. Epub 2009 Dec 18. PMID:20080763
- CCR1 and CCR5 promote hepatic fibrosis in mice.
Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA, Llovet JM, Brenner DA, Schwabe RF. J Clin Invest. 2009 Jul;119(7):1858-70.. PMID: 19603542 - TLR4 enhances TGF-beta signaling and hepatic fibrosis.
Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. Nat Med. 2007 Nov;13(11):1324-32. Epub 2007 Oct 21. PMID: 17952090
Contact the Seki Lab
8700 Beverly Blvd.
Davis Building, Rooms 2099, 2029
Los Angeles, CA 90048